Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment
Crossref DOI link: https://doi.org/10.1007/s12185-017-2239-8
Published Online: 2017-04-13
Published Print: 2017-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Takahashi, Naoto http://orcid.org/0000-0002-6758-3787
Nakaseko, Chiaki
Kobayashi, Yukio
Miyamura, Koichi
Ono, Chiho
Koide, Yuichiro
Fujii, Yosuke
Ohnishi, Kazunori
Funding for this research was provided by:
Pfizer Inc.
License valid from 2017-04-13